Related references
Note: Only part of the references are listed.Influence of Liver Cirrhosis on the Pharmacokinetics, Pharmacodynamics, and Safety of Tezosentan
Jasper Dingemanse et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Vascular biology and pathobiology of the liver: Report of a single-topic symposium
Yasuko Iwakiri et al.
HEPATOLOGY (2008)
Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects
J Dingemanse et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Determination of tezosentan, a parenteral endothelin receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometry
PLM van Giersbergen et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2003)
In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans
A Treiber et al.
XENOBIOTICA (2003)
Intrahepatic heterogeneity of hepatic venous pressure gradient in human cirrhosis
S Keiding et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2002)
Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist
J Dingemanse et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2002)
Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1:: differential effects of acute and chronic ETA receptor blockade
M Burkhardt et al.
JOURNAL OF HYPERTENSION (2000)
Share Paper
